Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 4,205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Completed Phase 1Phase 2 Interventional Results available

FX-322 in Sensorineural Hearing Loss

NCT03616223
View directory record Official record
Conditions
Sensorineural Hearing Loss
Interventions
FX-322, Placebo
Drug
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 17, 2026, 6:49 PM EDT
Recruiting Phase 2 Interventional

Dupilumab in the Treatment of Pediatric Alopecia Areata

NCT05866562
View directory record Official record
Conditions
Alopecia Areata
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Irvine, California • San Diego, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

NCT01339897
View directory record Official record
Conditions
Healthy
Interventions
5 mg/N6022, Placebo, 10mg/N6022, 20mg/N6022
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 17, 2026, 6:49 PM EDT
Recruiting Phase 3 Interventional

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07184996
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
118
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies

NCT00822523
View directory record Official record
Conditions
Muscle Strength, Botulinum Toxins, Type A
Interventions
Botulinum Toxin, Type A, Saline
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 54 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

NCT04999527
View directory record Official record
Conditions
Healthy Volunteer
Interventions
DISC-0974, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

NCT06609460
View directory record Official record
Conditions
Influenza
Interventions
CD388 Injection, Placebo
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 63 Years
Enrollment
5,071 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
56
States / cities
Anniston, Alabama • Cullman, Alabama • Tempe, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

NCT04856982
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Interventions
Tofersen, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 4 Interventional

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

NCT00240253
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
34
States / cities
Phoenix, Arizona • Concord, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

NCT02159053
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Anniston, Alabama • Upland, California • Aventura, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

NCT04078022
View directory record Official record
Conditions
Shigella
Interventions
SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone for Post-cesarean Delivery Pain

NCT01812057
View directory record Official record
Conditions
Pain, Postoperative, Postoperative Nausea and Vomiting
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Results available

Bay98-7196, Dose Finding / POC Study

NCT02203331
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 17, 2026, 6:49 PM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

NCT01389895
View directory record Official record
Conditions
Cutaneous Lupus, Lupus
Interventions
AMG 557, AMG 557 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 17, 2026, 6:49 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

NCT06248619
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Tucson, Arizona • Orland Park, Illinois • Ann Arbor, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Ribupatide, Placebo
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

BCG Vaccine for Health Care Workers as Defense Against COVID 19

NCT04348370
View directory record Official record
Conditions
Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
Interventions
BCG Vaccine, Placebo Vaccine
Biological
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 75 Years
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Bryan, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

NCT05901636
View directory record Official record
Conditions
Influenza Prevention
Interventions
INFLUENZA G1 mHA, Placebo, Al(OH)3
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 45 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 17, 2026, 6:49 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

NCT07229911
View directory record Official record
Conditions
Healthy Volunteers, Primary Sclerosing Cholangitis
Interventions
TAK-781, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Early Phase 1 Interventional

Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population

NCT01382771
View directory record Official record
Conditions
Low Back Pain
Interventions
Intra-articular corticosteroid injection, Intra-articular saline injection
Drug
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 17, 2026, 6:49 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee

NCT01668511
View directory record Official record
Conditions
Osteoarthritis
Interventions
ABT-981, Placebo
Biological
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
40 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 17, 2026, 6:49 PM EDT